Encouraging efficacy data have been obtained in the hepatitis C virus (HCV) chimpanzee
model using prophylactic vaccines comprising adjuvanted recombinant envelope …

There is no vaccine for HCV and the only available treatment, IFNα alone or in combination
with ribavirin, has proven efficacious in less than 50% of patients. Given that approximately …

Natural cross-protective immunity is induced after spontaneous clearance of primary
hepatitis C virus (HCV) infection. Although this suggests that effective prophylactic vaccines …

Development of an effective vaccine against the hepatitis C virus (HCV) has long been
defined as a difficult challenge due to the considerable variability of this RNA virus and the …

New drugs to treat hepatitis C are expected to be approved over the next few years which
promise to cure nearly all patients. However, due to issues of expected drug resistance …

Hepatitis C virus (HCV) is a blood borne disease estimated to chronically infect 3% of the
worlds' population causing significant morbidity and mortality. Current medical therapy is …

Despite major advances in the understanding and treatment of hepatitis C, a preventive
vaccine remains elusive. The marked genetic diversity and multiple mechanisms of …

Approximately 170 million individuals, representing 3% of the global population, are infected
with hepatitis C virus (HCV). Whereas strategies for antiviral therapies have markedly …

Prevention of hepatitis C virus (HCV) infection by vaccination has been a priority since
discovery of the virus and the need has not diminished over the past 25 years. Infection rates …

Unless urgently needed to prevent a pandemic, the development of a viral vaccine should
follow a rigorous scientific approach. Each vaccine candidate should be designed …